Equities Analysts Offer Predictions for RAPP Q3 Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimate for Rapport Therapeutics to ($0.79), down from a prior estimate of ($0.70), while maintaining a "Buy" rating and a price target of $31.00.
• Rapport Therapeutics recently reported quarterly earnings of (0.75) EPS, exceeding the consensus estimate of (0.87) EPS by $0.12.
• Insider David Bredt sold 8,500 shares of Rapport Therapeutics stock for approximately $119,000, reducing their position by 1.92%.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for shares of Rapport Therapeutics in a report released on Monday, August 11th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.79) for the quarter, down from their previous estimate of ($0.70). HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($3.80) EPS, FY2028 earnings at ($4.61) EPS and FY2029 earnings at ($4.22) EPS.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.12.

Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $28.00 price target on shares of Rapport Therapeutics in a research note on Tuesday, July 8th.

Rapport Therapeutics Stock Down 1.6%

Shares of RAPP stock traded down $0.24 during mid-day trading on Wednesday, hitting $14.70. 146,287 shares of the stock were exchanged, compared to its average volume of 161,777. The company has a market cap of $536.52 million, a PE ratio of -5.88 and a beta of 0.62. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74. The firm has a fifty day moving average of $13.52 and a 200 day moving average of $11.97.

Insiders Place Their Bets

In other news, insider David Bredt sold 8,500 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $14.00, for a total transaction of $119,000.00. Following the completion of the sale, the insider owned 435,142 shares in the company, valued at $6,091,988. This trade represents a 1.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.57% of the stock is owned by company insiders.

Institutional Trading of Rapport Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RAPP. Bank of America Corp DE increased its holdings in Rapport Therapeutics by 62.5% in the 2nd quarter. Bank of America Corp DE now owns 12,127 shares of the company's stock valued at $138,000 after purchasing an additional 4,666 shares during the last quarter. Acuta Capital Partners LLC lifted its position in shares of Rapport Therapeutics by 22.0% during the 2nd quarter. Acuta Capital Partners LLC now owns 20,000 shares of the company's stock worth $227,000 after purchasing an additional 3,600 shares during the last quarter. Alliancebernstein L.P. lifted its position in Rapport Therapeutics by 4.1% in the second quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company's stock valued at $13,129,000 after acquiring an additional 45,063 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Rapport Therapeutics by 27.2% in the second quarter. The Manufacturers Life Insurance Company now owns 100,424 shares of the company's stock valued at $1,142,000 after acquiring an additional 21,493 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Rapport Therapeutics in the second quarter valued at $2,270,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.